A possible increased risk of metamizole‐associated neutropenia among COVID‐19 patients

Lerman, Tsahi T.; Sagi, Moshe; Shafir, Yair; Sheena, Liron; Cohen, Eytan; Goldberg, Elad; Krause, Ilan

doi:10.1111/bcp.14703

Cited by 5 publications

(3 citation statements)

References 37 publications

(63 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In contrast, metamizole sodium has been associated with neutropenia and agranulocytosis by activating T lymphocytes that eliminate neutrophils in SARS-CoV-2 infection. Therefore, this drug could reduce the immune response, increasing mortality [ 60 ].…”

Section: Discussionmentioning

confidence: 99%

Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

et al. 2023

View full text Add to dashboard Cite

During the pandemic, some mortality-related factors were age, sex, comorbidities (obesity, diabetes mellitus, and hypertension), recovery time, hospitalizations, and biochemical markers. The present work aimed to identify the mortality and survival factors in adults with moderate and severe pneumonia due to COVID-19 during the first and second waves of the pandemic in Mexico at a third-level hospital (High-Specialty Regional Hospital of Ixtapaluca (HRAEI), Ixtapaluca, Estado de Mexico, Mexico). A database was generated using information from the electronic clinical records of patients hospitalized from December 2021 to August 2022. Survival analysis was performed associating age, sex, longer recovery times, and some drugs. The risk factors found were age in the patients between 40 and 60 years (OR = 1.70), male sex (OR = 1.53), the presence of comorbidities (OR = 1.66) and hypertension (OR = 2.19), work occupation (construction workers OR = 5.22, factory workers OR = 3.13, unemployed OR = 2.93), the prehospital use of metamizole sodium (OR = 2.17), cough (OR = 1.73), and in-hospital oxygen therapy (reservoir mask OR = 6.6). The survival factors found in this study were working in the healthcare field (OR = 0.26), the prehospital use of certain medications (paracetamol OR = 0.65, dexamethasone OR = 0.55, and azithromycin OR = 0.47), presenting ageusia (OR = 0.5) and hyporexia (OR = 0.34), and the time using in-hospital oxygen therapy (device 1 OR = 0.72). Prehospital treatment needs to be reevaluated as dexamethasone and azithromycin proved to be protective factors. Likewise, providing aggressive oxygen therapy during hospital admission decreased mortality risk.

show abstract

Section: Discussionmentioning

confidence: 99%

Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Previous studies do not generally mention neutropenia and lymphocytosis as a manifestation of COVID-19 infection. To the best of our knowledge, the phenomenon is only described in a few case reports [ 30 , 31 ], or in patients with a concomitant hematological malignancy or solid tumor [ 32 – 34 ]. Kannengiesser et al .…”

Section: Discussionmentioning

confidence: 99%

Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder

Bergantini¹,

Baldassarri²,

d’Alessandro³

et al. 2023

Respir Res

View full text Add to dashboard Cite

Background Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) is a novel coronavirus that caused an ongoing pandemic of a pathology termed Coronavirus Disease 19 (COVID-19). Several studies reported that both COVID-19 and RTEL1 variants are associated with shorter telomere length, but a direct association between the two is not generally acknowledged. Here we demonstrate that up to 8.6% of severe COVID-19 patients bear RTEL1 ultra-rare variants, and show how this subgroup can be recognized. Methods A cohort of 2246 SARS-CoV-2-positive subjects, collected within the GEN-COVID Multicenter study, was used in this work. Whole exome sequencing analysis was performed using the NovaSeq6000 System, and machine learning methods were used for candidate gene selection of severity. A nested study, comparing severely affected patients bearing or not variants in the selected gene, was used for the characterisation of specific clinical features connected to variants in both acute and post-acute phases. Results Our GEN-COVID cohort revealed a total of 151 patients carrying at least one RTEL1 ultra-rare variant, which was selected as a specific acute severity feature. From a clinical point of view, these patients showed higher liver function indices, as well as increased CRP and inflammatory markers, such as IL-6. Moreover, compared to control subjects, they present autoimmune disorders more frequently. Finally, their decreased diffusion lung capacity for carbon monoxide after six months of COVID-19 suggests that RTEL1 variants can contribute to the development of SARS-CoV-2-elicited lung fibrosis. Conclusion RTEL1 ultra-rare variants can be considered as a predictive marker of COVID-19 severity, as well as a marker of pathological evolution in pulmonary fibrosis in the post-COVID phase. This notion can be used for a rapid screening in hospitalized infected people, for vaccine prioritization, and appropriate follow-up assessment for subjects at risk. Trial Registration NCT04549831 (www.clinicaltrial.org)

show abstract

“…Adható láz-és fájdalomcsillapításra, kedvező a mellékhatásprofil, kedvezőbb a potenciálisan előnyös hatás. 3 új beteget regisztráltak COVID-19-ben kialakult neutropeniával metamizol adása után, emiatt körültekintés szükséges, gondolni kell erre a szövődményre [35].…”

Section: Röviden Néhány Nsaid-rólunclassified

Fájdalomtünetek és a fájdalomcsillapítás lehetőségei SARS-CoV-2-környezetben

Almási

2021

View full text Add to dashboard Cite

Összefoglaló. Az új koronavírusként megismert SARS-CoV-2-fertőzés legsúlyosabb szövődményeként a gyulladásos folyamatok jelátvivő molekuláinak elszabadulása – az ún. citokinvihar – kritikus légzési elégtelenséggel társuló akut respirációs diszfunkciós szindrómát vagy többszervi gyulladásos szindrómát okoz. Mostanáig igazolódott, hogy a fertőzések legnagyobb részben tünetmentesen vagy enyhe tünetekkel zajlanak. A betegség minden szakaszában előfordulhat enyhe vagy középsúlyos, ritkábban intenzív fájdalom, melyek enyhítésére számos fájdalomcsillapítási lehetőség áll rendelkezésre. A pandémia kezdete óta foglalkoznunk kell a tünetek enyhítésével, akár infektológiai osztályon, akár műtéti ellátás alkalmával. A betegek hazaengedését követően figyelmet kell fordítanunk az intenzív osztályos ellátás utáni és a COVID–19-et követő tünetek és fájdalmak értékelésére. Időszerű átfogó összefoglalónkban hangsúlyozzuk a különböző fájdalomcsillapítók szerepét a COVID–19-fertőzéssel összefüggő fájdalommal járó folyamatokban. Orv Hetil. 2021; 162(38): 1511–1519. Summary. As the most severe consequence of the new coronavirus SARS-CoV-2 infection, the cytokine storm – caused by the liberalization of several inflammatory mediators – engenders critical respiratory dysfunction syndrome or multisystem inflammatory syndrome. The most proportion of infections has proven symptomless or with very mild signs of disease so far. Mild, moderate, or rarely intense pain can occur in every phase of the disease, for the treatment of which more than a few analgesic possibilities are readily available. From the start of the pandemic, we have been concerning to ameliorate the symptoms, in either the department of infectology, or operating suites. The post-intensive care pain and post-COVID symptoms should be evaluated and treated after discharge. In this timely and comprehensive article, the role and importance of different analgesics are articulated regarding the COVID-associated painful conditions. Orv Hetil. 2021; 162(38): 1511–1519.

show abstract

A possible increased risk of metamizole‐associated neutropenia among COVID‐19 patients

Cited by 5 publications

References 37 publications

Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

Mortality and Survival Factors in Patients with Moderate and Severe Pneumonia Due to COVID-19

Ultra-rare RTEL1 gene variants associate with acute severity of COVID-19 and evolution to pulmonary fibrosis as a specific long COVID disorder

Fájdalomtünetek és a fájdalomcsillapítás lehetőségei SARS-CoV-2-környezetben

Contact Info

Product

Resources

About